Overview of ROTER Paracof

Property	Description
Active ingredients	Paracetamol (Acetaminophen), Caffeine
Form	Tablet (Oral Preparation)
Pharmacological class	Analgesic-Antipyretic Combination
Common use	Symptomatic relief of pain and fever
Origin	Synthetic

ROTER Paracof is a brand of fixed-dose combination medicine, manufactured as a synthetic, oral preparation in the form of a tablet. This product is classified within the Analgesic-Antipyretic Combination pharmacological group, designed for systemic symptomatic relief. It is typically positioned as an over-the-counter (OTC) option for adults and adolescents seeking relief from general discomfort.

This combination strategy is clinically recognized for delivering a comprehensive approach to managing common symptoms. The oral route ensures systemic absorption of both active compounds. The inclusion of Caffeine in analgesic combinations is supported by pharmacological studies into combination pain relievers.

What Active Ingredients Does ROTER Paracof Contain?

The composition of ROTER Paracof is defined by the inclusion of two active ingredients: Paracetamol (Acetaminophen) and Caffeine. Paracetamol acts as the primary agent for the relief of pain and fever, while Caffeine serves as an adjuvant to augment its effect.

Paracetamol mediates its effects by influencing prostaglandin synthesis within the central nervous system, thereby regulating the perception of pain signals and the body's temperature regulation. The addition of Caffeine is a mild psychoanaleptic agent, included in the formulation to boost the overall analgesic efficacy of Paracetamol. A review of such combinations concluded that Caffeine provides a clinically relevant increase in pain relief when combined with Paracetamol.

What is the General Purpose of This Combination?

The general purpose of the ROTER Paracof combination is to provide effective symptomatic treatment by simultaneously addressing pain and elevated body temperature associated with various common, non-severe ailments. This focused approach offers systemic relief from these two primary discomforts.

For instance, this medication is useful for patients seeking relief from the general discomfort and mild fever accompanying a common cold or flu-like illness. The combined formulation ensures a targeted strategy for managing both the patient’s discomfort (analgesia) and fever (antipyresis), thereby supporting general well-being during periods of minor illness.

What side effects are possible with ROTER Paracof?

Possible Side Effects and Safety Information

The safety profile for ROTER Paracof, a combination of Paracetamol (Acetaminophen) and Caffeine, is officially defined by specific adverse reaction categories and safety constraints documented in regulatory labeling. The effects are classified into those related to the Paracetamol component and those linked to the stimulant properties of Caffeine.

Official Adverse Reaction Categories

Adverse reactions are classified by frequency and System-Organ Class (SOC) as per regulatory standards. Very rare, serious effects associated with Paracetamol include Thrombocytopenia (low platelet count), Agranulocytosis, Anaphylaxis, and severe Hepatic Dysfunction. Less frequently observed, non-serious effects, often linked to the Caffeine component, include Nervousness, Insomnia, Restlessness, and Palpitations, which are typically classified with a frequency not known from available data.

Key systems involved, as listed in the label, are Hepatobiliary disorders, Blood and lymphatic system disorders, Immune system disorders, and Psychiatric disorders.

Serious Adverse Reactions and Population Constraints

Serious adverse reactions explicitly documented include Acute Liver Failure (Hepatotoxicity), which is the most critical risk associated with exceeding the maximum daily dose of Paracetamol or co-administering with other Paracetamol products. Rare, potentially fatal dermatological risks such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are also officially documented.

Specific safety constraints for populations exist: the medication is generally not recommended during pregnancy due to potential risks from Caffeine consumption and is contraindicated or requires caution in individuals with severe Hepatic Impairment due to heightened risk of Paracetamol toxicity. Additionally, long-term use has been associated with the potential development or worsening of Medication Overuse Headache.

Overdose and Emergency Response

Overdose and When to Seek Help

ROTER Paracof overdose is a medical emergency that requires immediate action. The toxic effects stem from its two active components, paracetamol (acetaminophen) and codeine.

Clinical Manifestations of Overdose

Component	Primary Symptoms
Paracetamol Toxicity (Delayed)	Nausea, vomiting, abdominal pain, loss of appetite, paleness, and sweating. Later signs (24–72 hours) include jaundice (yellowing of skin/eyes), confusion (encephalopathy), and signs of liver or kidney failure. Symptoms may be delayed for 24 hours or more, even with a dangerous dose.
Codeine Toxicity (Acute)	Pinpoint pupils, profound drowsiness, dizziness, confusion, and most critically, shallow or slow breathing (respiratory depression). This can rapidly progress to loss of consciousness and coma.

Required Emergency Actions

Seek immediate medical help if you suspect an overdose, even if you or the person who took the medicine feels well. Timeliness is critical for effective treatment, particularly for the paracetamol component. Treatment with the antidote N-acetylcysteine is most effective when administered within eight hours of ingestion.

Call emergency services right away if any of the following signs are present:

Shallow, slow, or labored breathing.
Extreme sleepiness, inability to wake, or loss of consciousness.
Blue-tinged lips or fingertips, or cold, clammy skin.
Severe, persistent nausea, vomiting, or abdominal pain.

Therapeutic Uses of ROTER Paracof

ROTER Paracof is commonly used in situations involving certain distressing symptoms. Its formulation is considered relevant for patients seeking additional symptomatic support to manage symptoms that interfere with daily functioning during acute episodes. The combination of paracetamol and caffeine is indicated for the treatment of most painful and febrile conditions, and is considered relevant in contexts involving heightened systemic burden, reflecting its role in symptom management.

Easing Discomfort and Supporting Stability

This medication is applied across domains where additional symptomatic support is needed, particularly is commonly used in situations involving symptoms related to physical discomfort and systemic imbalance. It is used in conditions presenting with acute episodes like headache, menstrual pain (dysmenorrhea), and discomfort associated with colds or flu-like illnesses.

This combination may assist with symptomatic management during episodes of heightened discomfort and supports the patient during difficult episodes by easing distress. The benefit is that it helps maintain a sense of stability and comfort during periods of acute illness by contributing to easing the overall symptom load.

Quick Fact: Relief for Episodic Pain ROTER Paracof is commonly used to help with symptoms related to episodic or fluctuating manifestations, and may provide temporary assistance in symptom stabilization when pain intensifies.

Eligibility and Restrictions for Use

Official Eligibility Profile for ROTER Paracof

Regulatory documents define specific populations permitted to use ROTER Paracof (Paracetamol/Caffeine) and those who are restricted or prohibited from use.

Category	Eligibility Status (As per Regulatory Labeling)
Approved Age Groups	Permitted for Adults and Adolescents (typically aged 12 or 16 years and over, depending on the region).
Children	Not recommended for use in children under 12 years of age in most jurisdictions.
Contraindications	Strictly prohibited in individuals with known hypersensitivity to Paracetamol or Caffeine, or those taking any other product containing paracetamol.
Pregnancy/Lactation	Not recommended for use during pregnancy or breastfeeding due to the caffeine content.
Organ Function	Use requires caution in patients with renal impairment or hepatic impairment, including non-cirrhotic alcoholic liver disease.
Comorbidities	Caution is advised for populations with conditions sensitive to caffeine, such as gout, hyperthyroidism, and arrhythmia, as well as asthmatic patients sensitive to aspirin.

The official criteria restrict use based on age minimums, ingredient allergies, and pre-existing health conditions that increase risk, ensuring the medicine is used only by eligible populations under labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for ROTER Paracof (Paracetamol/Caffeine combination), as defined by governmental regulatory documents.

Contraindicated and Restricted Combinations

Co-administration with other medicines containing Paracetamol (Acetaminophen) is formally contraindicated to prevent exceeding the maximum safe dose, which carries a risk of severe liver damage. Regular excessive intake of alcohol (three or more drinks per day) is also officially documented to increase the risk of Paracetamol-related hepatotoxicity. Additionally, consumption of other dietary sources of caffeine (such as coffee, tea, and cola drinks) should be limited to prevent excessive total caffeine intake and associated central nervous system stimulant effects.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class	Official Interaction Description
Oral Anticoagulants (e.g., Warfarin)	Prolonged, regular daily use of Paracetamol may enhance the anticoagulant effect, increasing bleeding risk.
Enzyme-Inducing Drugs (e.g., Carbamazepine, Phenytoin)	Increase the formation of toxic Paracetamol metabolites, raising the risk of hepatic damage.
Metoclopramide / Domperidone	Increase the speed of Paracetamol absorption.
Colestyramine	Reduces the rate and extent of Paracetamol absorption, requiring a one-hour separation of doses.
Flucloxacillin	Associated with high anion gap metabolic acidosis, particularly in patients with severe renal impairment.

These documented patterns define the necessary constraints for use, focusing on mitigating metabolic and pharmacokinetic risks as outlined in official labeling.

Mechanism of Action

ROTER Paracof contains paracetamol and caffeine. Paracetamol’s action is primarily centered on the central nervous system (CNS).

Paracetamol acts as an inhibitor of the enzyme cyclooxygenase (COX), selectively within the brain and spinal cord, reducing the peroxidation step required for the enzyme's activity. This intracellular action decreases the synthesis of prostaglandin E2 (PGE2) in the hypothalamus, modulating the thermal set-point and resulting in systemic heat dissipation. The analgesic action also involves the enhancement of the descending serotonergic inhibitory pain pathway through mechanisms that may include the indirect modulation of opioid receptors or activation of the endocannabinoid system, potentially via the metabolite AM404 acting as an agonist at the transient receptor potential vanilloid-1 (TRPV1) receptor.

Caffeine, a methylxanthine, acts as a non-selective antagonist at adenosine receptors, primarily the A1 and A2A subtypes. This antagonism blocks the inhibitory effects of endogenous adenosine on central nervous system activity, modulating neurotransmitter release and neuronal excitability.

Dosage and Administration Information

How to Use ROTER Paracof: Administration Guidelines

ROTER Paracof, an oral tablet containing Paracetamol 500 mg and Caffeine 65 mg, is administered for short-term, symptomatic relief according to specific regimens.

Administration Scope

Instruction	Detail
Route of Administration	The medicine is strictly for oral administration.
Standard Single Dose (Adults ge 16 years)	Two tablets (1000 mg Paracetamol / 130 mg Caffeine).
Dose Frequency and Interval	The dose must not be repeated more frequently than every 4 hours.
Maximum Daily Dose (Adults)	The total dose must not exceed 8 tablets (4000 mg Paracetamol / 520 mg Caffeine) in any 24-hour period.
Duration of Use	Use should not continue for longer than 3 days unless otherwise instructed by a healthcare professional.
Administration Condition	Tablets are to be swallowed whole with water.

Population-Specific Use

Standard guidelines define specific dosage guidelines for younger patients. The medicine is not recommended for children under 12 years of age.

Age Group	Single Dose	Maximum Daily Dose (24h)
Adolescents (12-15 years)	One tablet (500 mg Paracetamol / 65 mg Caffeine)	4 tablets (2000 mg Paracetamol / 260 mg Caffeine).

Procedural Context

Patients must account for all dietary and medicinal sources of caffeine while using this product to ensure that the total daily intake does not exceed the maximums. Guidelines also require that individuals with diagnosed impaired kidney or liver function seek medical advice before use, as the dose may need to be reduced or the dosing interval prolonged. The medicine is used as needed for symptoms and does not follow a fixed maintenance schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for ROTER Paracof

Evidence Landscape for Acute Pain

Clinical evaluation for the paracetamol/caffeine combination relies on Randomized Controlled Trials (RCTs) and meta-analyses that explore outcomes related to physical discomfort. This research examined short-term, acute pain models, such as dental or post-partum pain, to monitor symptom change. Studies observed patterns where the combination was studied against a placebo, and research compared it against paracetamol alone, monitoring differences in symptom change over short periods, typically four to six hours post-dose. The results apply only to the specific populations and conditions studied, and long-term effects are not fully established.

Evidence for Episodic Headache and Migraine

The evidence base for studies exploring the combination in the context of headaches relies on RCTs exploring episodic symptom patterns in adults. These studies examined specific measures like the time interval to symptom reporting. Studies reported patterns of measurable outcomes across numerous trials focused on episodic tension-type headache. For acute migraine pain, research has explored the combination, but evidence quality varies, with findings sometimes being discussed alongside the triple combination analgesic. Data for certain groups remain insufficient, as the research primarily addressed acute, episodic relief rather than chronic management.

Research Gaps and Special Populations

Research exploring temporary physiological imbalance was primarily conducted in adults (typically 18 to 65 years), and data for certain groups remain insufficient due to focused sample sizes. For example, there are few data available from dedicated trials for older adults (over 65 years) or for patients with co-existing health conditions (comorbidities). Key limitations include the fact that long-term effects are not fully established, and comparative evidence is lacking against many other combination analgesics. Certainty remains low for long-term or highly specific clinical scenarios.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about ROTER Paracof (FAQ)

Q: How quickly can someone expect to notice the effects of ROTER Paracof?

Pharmacokinetic data referenced in official product information suggests that the medicine generally begins to reach its effective concentration within 30 minutes to one hour after oral ingestion. This time frame represents a general expectation, and the actual onset of effect can vary between individuals.

Q: What is the expected duration of the effects of ROTER Paracof?

Studies and regulatory guidelines indicate that the pain-relieving effects typically last for approximately four to six hours. This duration is consistent with the minimum interval between doses referenced in official guidelines.

Q: Are there any specific foods or drinks that should be avoided when using ROTER Paracof?

Regulatory documents state that certain substances should be limited or avoided. Official labeling states that regular excessive alcohol intake is associated with an increased risk of liver damage from Paracetamol, and should therefore be avoided. Limiting the consumption of other dietary sources of caffeine, such as coffee or tea, is also noted to prevent excessive total caffeine intake.

Q: Can older adults generally use ROTER Paracof?

The medicine is generally approved for use in adults. However, official regulatory documents advise caution for older adults (typically over 65 years). Due to the potential for underlying health conditions or changes in organ function, consultation with a healthcare professional is described in official guidelines.

Q: Are there any known issues with using ROTER Paracof for people with kidney concerns?

Regulatory documents advise that use requires caution in patients with renal impairment (reduced kidney function). Official documents state that individuals with impaired kidney function require caution, and dose adjustment or prolongation of the dosing interval is sometimes indicated under medical supervision.

Q: Is ROTER Paracof described as a medicine that can be taken on a long-term basis?

Official documentation describes ROTER Paracof as a product intended only for short-term, symptomatic use. Official warnings state that using the medicine for prolonged periods is not recommended and has been associated with the potential development of a condition called Medication Overuse Headache.

Q: What is the maximum number of days ROTER Paracof is typically recommended for use?

Official patient information leaflets typically state that use should not be continued for longer than three days. Continued use beyond this period is defined in official labeling as a reason to seek advice from a healthcare professional.

Q: What is the distinction between a common and an uncommon side effect of ROTER Paracof?

In regulatory safety reporting, side effects are classified by their frequency of occurrence. A common side effect is typically defined as occurring in 1 to 10 out of every 100 people. An uncommon side effect is less frequent, generally occurring in 1 to 10 out of every 1,000 people.

Q: Are there documented cases of allergic reactions to ROTER Paracof?

Yes, official labeling lists known hypersensitivity (severe allergic reaction) to either active ingredient as a strict reason to not use the medicine. Additionally, serious allergic reactions, such as anaphylaxis, are listed as a very rare potential adverse effect.

Q: How often are the common side effects of ROTER Paracof reported?

Common side effects are defined in official documents as those occurring in 1% to 10% of users. For this medicine, specific common side effects are often linked to the caffeine component, such as nervousness and insomnia.

Q: Is it typical for ROTER Paracof to cause temporary drowsiness?

The main neurological effects listed in regulatory documents are primarily related to the stimulant action of caffeine, such as restlessness and insomnia. The medicine is generally not expected to cause drowsiness, but individual responses to the medicine can vary.

Q: Does ROTER Paracof interact with common herbal supplements?

While official information primarily details interactions with specific prescription drugs, the use of certain herbal supplements may still require medical consultation. Some herbal supplements, such as St. John's Wort, are noted to act as enzyme inducers, a mechanism that can interact with the medicine, meaning consultation is generally recommended.

Q: What should be done if someone misses a time to use ROTER Paracof?

Official patient instructions advise that if a dose is missed, it should be taken as soon as possible, provided the next dose is not due too soon. Regulatory guidelines specify that a double dose should not be taken to compensate for a forgotten one.

Q: What is the general conclusion of the research evidence for ROTER Paracof?

Studies and clinical trials cited in regulatory documents generally support that the Paracetamol and Caffeine combination provides a statistically significant increase in pain relief compared to placebo or Paracetamol alone. This evidence applies to the short-term treatment of the acute conditions studied.

Q: Has ROTER Paracof been studied in children or adolescents?

While regulatory documents include specific dosing instructions for adolescents (aged 12-15 years), the main body of clinical evidence often cited in the official summaries is primarily derived from research conducted in adult populations.

Q: Are there any specific laboratory tests that can be affected by ROTER Paracof?

The Paracetamol component is known to potentially interfere with certain laboratory tests used to measure substances in the blood, such as uric acid and glucose levels. It is generally noted that medical staff should be informed of the medicine’s use before these tests are conducted.

Q: Is ROTER Paracof habit-forming or described as having potential for dependence?

Official regulatory warnings for this combination medicine, which does not contain controlled substances, do not typically include a statement regarding a risk of habit formation or abuse potential. The risk of dependence is considered low.

Q: Can ROTER Paracof cause issues with mental clarity or driving?

Regulatory documents state that ROTER Paracof is not expected to impair the ability to drive or operate machinery. However, official guidelines indicate that an individual’s reaction to the medicine should be noted before engaging in activities that require full attention.

Q: What official body is responsible for regulating ROTER Paracof?

The regulation of ROTER Paracof, as a pharmaceutical product, is overseen by the national drug authority in the country where the medicine is marketed. Examples include the MHRA in the UK or the FDA in the United States.

Q: What is the research status regarding long-term safety of ROTER Paracof?

Regulatory summaries state that long-term safety is not fully established. The existing clinical evidence is limited to short-term studies, as the medicine is intended only for the management of acute symptoms.

Q: Is it expected to feel completely normal while using ROTER Paracof?

Due to the stimulant effects of the caffeine component, a person may experience common documented effects such as nervousness or restlessness. Because of these potential effects, it is possible for a patient to feel that they are not entirely normal while the medicine is active.

Q: Can individuals with a history of certain heart issues use ROTER Paracof?

Official documents advise caution for populations whose conditions may be sensitive to caffeine, such as those with existing heart rhythm problems (arrhythmia). Regulatory documents state that individuals with heart issues should consult a healthcare professional before use.

Q: Is the onset of action different when taken with food versus without food?

Pharmacokinetic data suggests that the absorption of Paracetamol may be delayed when the medicine is taken with food. This means that the time until the onset of the pain-relieving effect may be slightly longer compared to taking it on an empty stomach.

Q: What happens in the body when the effect of ROTER Paracof wears off?

As the medicine is eliminated from the body, its components are metabolized (broken down) primarily by the liver and then excreted by the kidneys. The wearing off of the symptomatic relief corresponds to the lowering of drug concentrations below the therapeutic level.

Q: What kind of studies provided the primary evidence for ROTER Paracof approval?

The primary evidence cited in official documents includes data gathered from Randomized Controlled Trials (RCTs) and systematic meta-analyses. These studies focused on short-term outcomes related to pain relief in models of acute pain.

Q: How is ROTER Paracof different from other similar-sounding medicines?

ROTER Paracof is specifically characterized by its fixed combination of the analgesic Paracetamol and the adjuvant Caffeine. Other medicines that sound similar may contain different active ingredients, ratios, or be intended for entirely different therapeutic uses.

How should ROTER Paracof be stored and disposed of?

The storage and disposal of ROTER Paracof must align with the instructions documented in the official regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Storage Requirement	Specification
Temperature	Store below 25 C or 30 C (varies by label).
Protection	Must be stored in the original package to protect from light and moisture.
Child Safety	Keep out of the reach and sight of children.
Stability Period	The typical shelf life is 4 to 5 years when stored correctly.

Disposal Instructions

Disposal Requirement	Specification
General Rule	Dispose of any unused or expired product in accordance with local requirements.
Prohibited	The product should not be discarded via wastewater or general household trash without following specific recommended preparation steps.

These official statements define the required temperature ceiling and environmental protection to maintain stability. Disposal is governed by the regulatory instruction to follow local guidelines, primarily utilizing take-back programs.

ROTER Paracof